Phase 3 long-term extension study of tolebrutinib in multiple sclerosis

Phase 3, open-label trial of tolebrutinib in multiple sclerosis (MS), primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Sanofi. Primary endpoints: Number of participants with adverse events and serious adverse events and Number of participants with potentially clinically significant abnormalities. Started May 2024; status: active, not recruiting.